Claims for Patent: 8,092,988

Summary for Patent: 8,092,988

Title:	Medium and method of deriving and using a mutated bacteria strain
Abstract:	A new strain of Bacillus anthracis derived from the Sterne vaccine strain of Bacillus anthracis by growth on a high-nitrate-concentration, 3-amino-L-tyrosine growth medium.
Inventor(s):	Parker; Jill E. (Floresville, TX), Kiel; Johnathan L. (Universal City, TX), Gifford; Homer (Hardy, AR), Alls; John L. (Floresville, TX), Morales, legal representative; Pedro J. (Floresville, TX)
Assignee:	The United States of America as represented by the Secretary of the Air Force (Washington, DC) N/A (N/A)
Application Number:	11/820,039
Patent Claims:	1. A composition comprising: about 55 g of trypticase soy broth (TSB) base; about 12 g potassium nitrate; about 100 mg luminol (5-amino-2 3-dihydro-1; 4-phthalazinedione); and about 80 mg 3-amino-L-tyrosine dihydrochloride per liter of water. 2. A method comprising: providing as a medium the composition of claim 1; and inoculating said medium with a paternal bacteria strain; whereby a mutated bacteria strain is produced. 3. The method of claim 2 wherein said paternal bacteria strain is Bacillus anthracis. 4. The method of claim 3 further comprising: introducing cells of said mutated bacteria strain into a laboratory animal; and producing delayed onset of death in said laboratory animal, compared to an animal into which said paternal bacteria strain is introduced. 5. The method of claim 2 wherein said paternal bacteria strain is the Sterne strain of Bacillus anthracis. 6. A method comprising: culturing in a medium a cell of the mutated strain of claim 2, under conditions permitting expression of protein products; and purifying one or more of said protein products from said cell or medium of said cell.

Details for Patent 8,092,988

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2023-06-20